MDG2 Stock Overview
A biotechnology company, focuses on the discovery and development of T-cell therapies for the treatment of cancer.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 2 more risks
Medigene AG Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €2.15 |
| 52 Week High | €5.40 |
| 52 Week Low | €1.71 |
| Beta | 0.84 |
| 11 Month Change | 0.23% |
| 3 Month Change | -7.54% |
| 1 Year Change | -38.71% |
| 33 Year Change | -71.96% |
| 5 Year Change | -82.01% |
| Change since IPO | -90.98% |
Recent News & Updates
Recent updates
Shareholder Returns
| MDG2 | AT Biotechs | AT Market | |
|---|---|---|---|
| 7D | 0% | -2.9% | -0.6% |
| 1Y | -38.7% | 0.3% | 6.9% |
Return vs Industry: MDG2 underperformed the Austrian Biotechs industry which returned 0.3% over the past year.
Return vs Market: MDG2 underperformed the Austrian Market which returned 6.9% over the past year.
Price Volatility
| MDG2 volatility | |
|---|---|
| MDG2 Average Weekly Movement | 9.5% |
| Biotechs Industry Average Movement | 7.2% |
| Market Average Movement | 3.5% |
| 10% most volatile stocks in AT Market | 5.8% |
| 10% least volatile stocks in AT Market | 1.7% |
Stable Share Price: MDG2 has not had significant price volatility in the past 3 months.
Volatility Over Time: MDG2's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of Austrian stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1994 | 87 | Selwyn Ho | www.medigene.com |
Medigene AG, a biotechnology company, focuses on the discovery and development of T-cell therapies for the treatment of cancer. The company’s end-to-end platform enables the development of T cell receptor engineered T cell (TCR-T) therapies for multiple tumor indications. Its pipeline includes MDG1015, a TCR-T therapy product to treat multiple solid tumor indications; MDG10xx to treat multiple solid tumor; and MDG1011, a TCR-T immunotherapy candidate, which is in clinical development to treat blood cancer.
Medigene AG Fundamentals Summary
| MDG2 fundamental statistics | |
|---|---|
| Market cap | €31.61m |
| Earnings (TTM) | -€15.93m |
| Revenue (TTM) | €7.45m |
4.2x
P/S Ratio-2.0x
P/E RatioIs MDG2 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MDG2 income statement (TTM) | |
|---|---|
| Revenue | €7.45m |
| Cost of Revenue | €1.49m |
| Gross Profit | €5.95m |
| Other Expenses | €21.89m |
| Earnings | -€15.93m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.08 |
| Gross Margin | 79.94% |
| Net Profit Margin | -213.98% |
| Debt/Equity Ratio | 0% |
How did MDG2 perform over the long term?
See historical performance and comparison